Brief: Unity Biotechnology Doses First Patients In Phase 2 ASPIRE Study of UBX1325 in DME
12/12/2023 13:05
Dec 12 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY DOSES FIRST PATIENTS IN PHASE 2 ASPIRE
STUDY
OF UBX1325 IN DME
* UNITY BIOTECHNOLOGY INC - INITIAL 16-WEEK DATA IS EXPECTED
IN Q4
OF 2024 AND 24-WEEK DATA EXPECTED IN Q1 OF 2025
Source text for Eikon: ID:nGNX27M4vM
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force